EGFR and oropharynx cancer: However, two recent randomized trials have studied this strategy in HPV‐positive patients with oropharyngeal cancer, concluding that, besides cetuximab resulting in lesser toxicities when administered with RT compared with cisplatin + RT, it was found to be inferior in OS.33, 34 These results suggest that de‐escalation strategy should be carefully used in clinical practice, and also that anti‐EGFR antibodies may not be the optimal therapies for this strategy.